Novel Approaches for Radiation Biodosimetry Assays and Devices Development (U01 Clinical Trial Not Allowed)
ID: 352010Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $350K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/352010

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-003.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Approaches for Radiation Biodosimetry Assays and Devices Development," aimed at advancing research in radiation exposure assessment. This initiative seeks to support the development of innovative biodosimetry assays and devices that can identify biomarkers of injury and assess absorbed doses, particularly in the context of public health emergencies involving radiation exposure. The funding will facilitate early- to mid-stage research with a total budget of approximately $4 million, allowing for 6-8 awards of up to $350,000 each per year, over a project duration of up to five years. Interested applicants must submit their proposals by May 31, 2024, and can find additional information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-24-003-Full-Announcement.html
    RFA-AI-24-003.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces a funding opportunity directed at developing novel biodosimetry assays and devices for radiation exposure assessment. This initiative, titled "Novel Approaches for Radiation Biodosimetry Assays and Devices Development," seeks to enhance medical preparedness against radiation injuries stemming from public health emergencies. The funding will support early- to mid-stage research to identify biomarkers indicating injury and create fast, reliable techniques for assessing absorbed doses and predicting health outcomes. The goal is to develop methods adequate for immediate field use in radiation incidents, particularly focused on distinguishing between exposed individuals and the "worried well." Key application details include an anticipated budget of $4 million for 6-8 awards, with each requesting no more than $350,000 in direct costs annually, and a project duration of up to five years. Applicants are encouraged to submit proposals addressing specific research gaps and to provide milestones for progress assessment. In summary, this funding opportunity aims to advance understanding and mitigation of radiation injuries through biomarker research, thereby enhancing the country’s preparedness for radiological emergencies.
    Similar Opportunities
    Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Integrating Biospecimen Science Approaches into Clinical Assay Development" (FON: PAR-25-325). This initiative aims to support extramural research focused on addressing preanalytical variability in the development and analytical validation of clinical assays utilizing biospecimens such as tumor biopsies and liquid biopsies. The program seeks to enhance the reliability of biomarker assays by investigating how various collection, processing, and storage conditions impact biomarker quantification, ultimately contributing to improved cancer diagnostics and treatment in precision medicine. Interested applicants can apply for funding of up to $250,000 annually for a period of five years, with the first application deadline set for January 4, 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-325.html.
    Long-Term Effects of Disasters on Healthcare Systems in Populations with Health Disparities (R01- Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Long-Term Effects of Disasters on Healthcare Systems in Populations with Health Disparities" (FON: PAR-24-109), aimed at supporting collaborative research into the impacts of disasters on healthcare systems serving vulnerable populations in the U.S. and its territories. The initiative focuses on understanding the long-term effects, defined as one year or more post-disaster, on access, delivery, and quality of healthcare services, with an emphasis on fostering resilience and mitigating disparities exacerbated by such events. Eligible applicants include a wide range of institutions, including educational organizations, nonprofits, and government entities, with a funding ceiling of $500,000. The application period opens on May 5, 2024, and closes on June 5, 2024, with further inquiries directed to NIH Grants Information at grantsinfo@nih.gov.
    NIEHS Worker Training Program’s HAZMAT Training at DOE Nuclear Weapons Complex (UH4 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIEHS Worker Training Program for HAZMAT training at the Department of Energy's Nuclear Weapons Complex. This initiative aims to provide training and education to workers involved in hazardous waste management and emergency response, focusing on preventing work-related harm and promoting health and safety in the workforce. The program is funded under the Superfund Amendments and Reauthorization Act of 1986 and is expected to allocate approximately $3 million across two awards. Interested applicants, specifically private institutions of higher education, should note that the application period opens with a synopsis expected on September 24, 2025, and closes on November 25, 2025. For further inquiries, contact Sharon D. Beard at 984-287-3237 or via email at beard1@niehs.nih.gov.
    Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators" through the National Cancer Institute (NCI). This initiative aims to support research focused on the identification and development of small molecules that can elucidate cancer biology and contribute to therapeutic advancements. The funding is intended for various eligible applicants, including educational institutions and non-profit organizations, with a flexible budget and a project duration of up to three years. Key deadlines include an application submission window starting January 5, 2025, and a closing date of September 7, 2026. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-153.html.
    Promoting a Basic Understanding of Chemical Threats to Skin (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Promoting a Basic Understanding of Chemical Threats to Skin," aimed at small businesses interested in researching the pathological mechanisms of skin injuries caused by toxic chemicals. The initiative seeks to elucidate the commonalities in the mechanisms of skin injuries from various vesicants, such as sulfur mustard and Lewisite, with the goal of identifying shared therapeutic targets and developing broad-spectrum medical countermeasures for mass casualty events. The estimated total program funding is $2,500,000, with approximately five awards expected, and interested applicants are encouraged to collaborate and prepare their proposals ahead of the anticipated application period, which is expected to open in early 2026. For further inquiries, potential applicants can contact Dr. Peter J. Koch at Peter.Koch@NIH.gov or by phone at 240-987-8325.
    Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for revision applications aimed at validating biomarker assays developed through NIH-supported research grants, specifically under the R01 mechanism, with a focus on enhancing their clinical application for cancer detection and treatment. This initiative seeks to accelerate the translation of molecular, cellular, and imaging markers into clinical settings, encouraging multidisciplinary collaborations among scientists, clinicians, and laboratory experts to adapt and validate these biomarkers for various cancer-related purposes. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and tribal governments, with funding available up to $150,000 for a project period of up to three years. Interested parties should note that the application deadline is October 13, 2026, and can find further details and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) for the development and screening of assays aimed at discovering small molecules that can serve as chemical probes, drugs, or immunomodulators. This initiative seeks to support research that elucidates disease biology and therapeutic targets, particularly focusing on cancer-related applications, including the development of assays, high-throughput screening, hit validation, and optimization of lead compounds. The opportunity is open to a wide range of eligible applicants, including educational institutions, nonprofits, and tribal organizations, with no cost-sharing requirement and a project period of up to three years. Interested parties should submit their applications electronically through Grants.gov by the deadline of September 7, 2026, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer," aimed at enhancing the validation and adoption of biomarkers and assays critical for cancer detection, diagnosis, and treatment response prediction. This initiative seeks projects that utilize established assays with demonstrated analytical validation for clinical use, fostering collaboration among scientific experts to address significant gaps in cancer research. The funding amount is capped at $250,000 per year for a project duration of up to three years, with applications due by October 14, 2026. Interested applicants can find more information and application details at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This funding aims to support innovative projects that develop technologies for analyzing and managing biospecimens in cancer research and clinical care, with a focus on proof-of-concept studies that demonstrate feasibility in areas such as cancer biology, early detection, and health disparities. The total estimated program funding is $4.7 million, with individual awards ranging from $50,000 to $150,000, and approximately 17 awards are expected to be made. Interested applicants can reach out to Dr. Kelly Crotty at Kelly.crotty@nih.gov or by phone at 240-255-0917 for further information, with applications due by April 10, 2026.
    NIEHS Worker Training Program’s SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIEHS Worker Training Program for small businesses to develop Technology-Enhanced Training Products aimed at improving health and safety training for hazardous materials (HAZMAT) workers and emergency responders. This initiative seeks applications for the SBIR E-Learning for HAZMAT and Emergency Response (R43/R44), focusing on innovative training solutions such as online courses, augmented reality, and serious gaming to enhance the training experience. The program is crucial for equipping workers with the necessary skills to protect themselves and their communities from hazardous materials exposure, with an estimated total funding of $688,000 available for approximately six awards. Interested applicants can reach out to Sharon D. Beard at NIEHS via email at beard1@niehs.nih.gov or by phone at 984-287-3237, with applications due by November 20, 2025, and anticipated awards announced by June 1, 2026.